<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962388</url>
  </required_header>
  <id_info>
    <org_study_id>RUXBETA trial</org_study_id>
    <nct_id>NCT02962388</nct_id>
  </id_info>
  <brief_title>The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line</brief_title>
  <official_title>A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective national multicenter randomized open label phase IIb RUXBETA trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open label, multicenter phase IIb study to evaluate the efficacy and safety of
      Ruxolitinib versus best available therapy in patients with high risk essential
      thrombocythemia, who are resistant or intolerant to hydroxyurea.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free patients</measure>
    <time_frame>month 12</time_frame>
    <description>Failure is defined by the occurrence of either intolerance and/or resistance to the second line therapy according to the protocol criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete hematologic response</measure>
    <time_frame>48 months</time_frame>
    <description>Number of Participants With normal Laboratory Values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE/SAE</measure>
    <time_frame>48 months</time_frame>
    <description>Rates, types and grades of AE/SAE related to the therapy, according to the NCI-CTCAE v4.0 classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median dose</measure>
    <time_frame>48 months</time_frame>
    <description>Median dose of the treatment received</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombotic and hemorrhagic events</measure>
    <time_frame>48 months</time_frame>
    <description>Cumulative incidence of thrombotic and hemorrhagic events incidence of progression into PV, secondary MF and MDS/acute leukemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>48 months</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Essential Thrombocythemia</condition>
  <arm_group>
    <arm_group_label>Reference therapy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational therapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib JAKAVI® Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing paradigm.
Maximum dose 25 mg BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anagrelide</intervention_name>
    <description>Anagrelide in the study, according to the investigator decision fom day 1 to 48 months</description>
    <arm_group_label>Reference therapy arm</arm_group_label>
    <other_name>ARM A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib (JAKAVI®)</intervention_name>
    <description>Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months</description>
    <arm_group_label>Investigational therapy arm</arm_group_label>
    <other_name>ARM B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFNα/ PegIFNα</intervention_name>
    <description>IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months</description>
    <arm_group_label>Reference therapy arm</arm_group_label>
    <other_name>ARM A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Target Population

          -  Men and women, age more than or equal18 years and less than 75 years.

          -  Confirmed diagnosis of Essential Thrombocythemia for at least 6 months, according to
             the 2008 WHO criteria, with a high-risk status.

          -  Patients must have a treatment history for ET that meet the definition of resistance
             or intolerance to hydroxyurea therapy according to the ELN criteria as follow:

               -  Platelets more than 600.0109/L after 3 months (12 weeks) of treatment at a dose
                  over 2g/day.

               -  Platelets more than 400.0 109/L and WBC less than 2.5109/L, whatever the dose of
                  HU.

               -  Platelets more than 400.0 109/L and Hb less than 10g/dl whatever the dose of HU.

               -  Leg ulcers or other unacceptable muco-cutaneous toxicity.

               -  HU-related fever.

          -  ECOG Performance Status (ECOG PS) less than or equal 2 at screening and at baseline.

        Adequate Organ Function:

          -  Direct bilirubin less than 2.0 times the institutional Upper Limit of Normal (ULN).

          -  Hepatic enzymes (AST, ALT) less than or equal 2.5 times the institutional ULN.

          -  Adequate renal function at screening as demonstrated by MDRD-eGFR more than 30
             mL/min/1.73m2.

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy during and after the study.

               -  A male subject of fathering potential must use an adequate method of
                  contraception to avoid conception during and after the study to minimize the risk
                  of pregnancy.

               -  For females and males, these restrictions apply for 24 hours after the last dose
                  of study drug.

          -  Women of childbearing potential must have a negative serum (beta-human chorionic
             gonadotropin hCG pregnancy test at Screening.

          -  Signed Written Informed Consent.

          -  Health insurance coverage.

        Exclusion Criteria:

          -  Patients with thrombocytosis related to another MPN than ET

          -  Patients previously treated with a JAK2 inhibitor, Anagrelide or Interferon-alpha and
             prior history of therapy other than Hydroxyurea

          -  Contraindication to Ruxolitinib, Anagrelide or Interferon-alpha (if no eligible for
             anagrelide), hypersensitivity to an excipient

        Medical history and concurrent diseases:

          -  Clinically significant cardiac disease (NYHA Class III or IV).

          -  Chronic hepatocellular disease.

          -  Subjects with impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of Ruxolitinib

          -  Subjects with clinically significant bacterial, fungal, parasitic or viral infection
             which requires therapy:

               -  Subjects with acute bacterial infections requiring antibiotic use should delay
                  screening/enrolment until the course of antibiotic therapy has been completed.

               -  Subjects with active hepatitis A, B or C or with HIV positivity at screening.

               -  Subjects with diagnosed primary immunodeficiency syndromes such as X-Linked a
                  gammaglobulinemia and common variable immune deficiency.

               -  Subject with medical history of tuberculosis

          -  History of progressive multifocal leucoencephalopathy (PML).

          -  Other malignant disease during the last 5 years prior to the inclusion except treated
             cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell
             carcinoma of the skin, with no evidence for recurrence in the past 3 years.

          -  History of significant bleeding disorder not related to the ET.

               -  Diagnosed congenital bleeding disorders,

               -  Diagnosed acquired bleeding disorder within one year (e.g. acquired anti-factor
                  VIII antibodies),

               -  Ongoing or recent (3 months) significant gastrointestinal bleeding.

          -  Subjects with an uncontrolled undercurrent illness or any concurrent condition that,
             in the investigator's opinion, would jeopardize the safety of the subject or
             compliance with the protocol.

          -  Subjects being treated concurrently with a potent systemic inhibitor of CYP3A4 at the
             time of screening.

          -  Subjects being treated concurrently with any prohibited medications.

          -  Women who are pregnant or breastfeeding are not eligible for this study.

          -  Inability to freely provide consent through judiciary or administrative condition.

          -  Ongoing participation to another clinical investigational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane GIRAUDIER, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>France Intergroupe Syndromes Myéloprolifératifs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LYDIA ROY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>France Intergroupe Syndromes Myéloprolifératifs</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphane GIRAUDIER, MD PD</last_name>
    <phone>+33149812800</phone>
    <email>stephane.giraudier@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie ROLLAND NEYRET, Mrs</last_name>
    <phone>+33476765096</phone>
    <email>VRolland-neyret@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>FILO</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mélanie COTTOT, Mrs</last_name>
      <phone>+33247478899</phone>
      <email>m.dupin@chu-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stéphanie ROY, Mrs</last_name>
      <phone>+33247381896</phone>
      <email>filo@univ-tours.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO site</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Anagrelide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>e crf</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

